Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Vorinostat | HDAC | HDAC | 5906.065 | uM | 39.50840 | 80.74350 | -0.9927 | -1.0000 | 1.5370 | 0.8548 | 0.9977 | 0.6586 | |
| AU565 | HER2amp | Luminal | GSK923295 | CENPE | Kinesin | 7793.001 | uM | 0.02405 | 0.02845 | -0.7415 | -0.6582 | 5.0000 | 0.9064 | 0.9803 | 1.1508 | |
| BT-474 | HER2amp | Luminal | Vorinostat | HDAC | HDAC | 5905.065 | uM | 65.67480 | 118.77110 | -0.9633 | -0.9775 | 1.8287 | 0.7654 | 0.9989 | 0.8461 | |
| 21MT-1 | HER2amp | - | Mebendazole | 13719.174 | uM | 31.97060 | 77.55140 | 0.0875 | -1.0000 | 1.2398 | 0.1610 | 0.8782 | 0.8124 | |||
| BT-474 | HER2amp | Luminal | XRP44X | ELK3 | MAPK | 12056.157 | uM | inf | 0.25218 | 0.6336 | 0.6521 | 1.1164 | 0.2064 | 0.5892 | 0.9748 | |
| AU565 | HER2amp | Luminal | GW-5074 | CRAF | MAPK | 5900.088 | uM | inf | 7.75810 | 0.6475 | 0.6473 | 4.9899 | 0.0383 | 0.9887 | 2.7830 | |
| BT-474 | HER2amp | Luminal | XRP44X | ELK3 | MAPK | 12291.157 | uM | 1.31810 | 1.41760 | -0.2813 | -0.2196 | 4.9996 | 0.4789 | 0.9519 | 0.5161 | |
| BT-474 | HER2amp | Luminal | XRP44X | ELK3 | MAPK | 12178.157 | uM | 3.83080 | 5.02370 | -0.3595 | -0.2713 | 1.5988 | 0.3017 | 0.9796 | 0.5528 | |
| AU565 | HER2amp | Luminal | Ibandronate | FDPS | 10880.143 | uM | 190.49250 | 139.95740 | 0.2035 | 0.1860 | 1.5087 | 0.1480 | 0.9763 | 1.6077 | ||
| BT-474 | HER2amp | Luminal | Z-Leu-Leu-Norvalinal | Proteasome | Proteasome | 14233.189 | uM | 0.23986 | 0.55671 | -0.9876 | -0.9894 | 1.2963 | 0.7600 | 0.9937 | 0.3780 | |
| 21MT-1 | HER2amp | - | Methylglyoxal | 13719.184 | uM | 680.32080 | 999.99990 | -0.9954 | -0.9645 | 2.7899 | 0.6345 | 0.9961 | 0.7600 | |||
| BT-474 | HER2amp | Luminal | Z-Leu-Leu-Norvalinal | Proteasome | Proteasome | 14119.189 | uM | 1.43850 | 2.09160 | -0.5407 | -0.5210 | 1.9072 | 0.4272 | 0.9968 | 1.2143 | |
| AU565 | HER2amp | Luminal | ICRF-193 | TOP2 | TOP | 10880.151 | uM | 1.03060 | 0.48809 | 0.2691 | 0.2426 | 0.8883 | 0.2612 | 0.9893 | 1.8509 | |
| BT-474 | HER2amp | Luminal | ZM-447439 | AURK | AURK | 12178.16 | uM | inf | inf | 0.5577 | 0.5577 | 0.0000 | 0.3142 | 0.4077 | 0.7392 | |
| BT-474 | HER2amp | Luminal | ZM-447439 | AURK | AURK | 12291.169 | uM | 2.74420 | 2.49370 | -0.0499 | 0.1902 | 5.0000 | 0.2447 | 0.7269 | 0.3548 | |
| AU565 | HER2amp | Luminal | IKK16 | IKK | NFKB | 5900.093 | uM | 3.11010 | 4.89820 | -0.7771 | -0.7902 | 2.0869 | 0.3658 | 0.9980 | 2.3084 | |
| BT-474 | HER2amp | Luminal | ZM-447439 | AURK | AURK | 12056.16 | uM | 18.20560 | 49.54740 | -0.4446 | -1.0000 | 1.0973 | 0.3126 | 0.7841 | 0.9124 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 5901.091 | uM | 19.04840 | 28.45990 | -0.8741 | -0.8850 | 2.5375 | 0.4460 | 0.9984 | 1.9229 | |
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 5900.092 | uM | 25.17290 | 35.4570 | -0.7508 | -0.7538 | 2.6838 | 0.3679 | 0.9995 | 2.6334 | |
| AU565 | HER2amp | Luminal | Ispinesib | KSP | Kinesin | 5900.067 | uM | 0.02287 | 0.02721 | -0.8045 | -0.5292 | 4.1590 | 0.8231 | 0.9793 | 2.4324 | |
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| AU565 | HER2amp | Luminal | Ispinesib | KSP | Kinesin | 5901.067 | uM | 0.01802 | 0.02217 | -0.9025 | -0.7242 | 4.3172 | 0.9599 | 0.9934 | 1.8762 |